Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses

Akihiro Otsuki, Ankita Patel, Kazue Kasai, Masataka Suzuki, Kazuhiko Kurozumi, E. Antonio Chiocca, Yoshinaga Saeki

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Replication-conditional (oncolytic) mutants of herpes simplex virus (HSV), are considered promising therapeutic alternatives for human malignancies, and chemotherapeutic adjuvants are increasingly sought to augment their efficacy. Histone deacetylase (HDAC) inhibitors are a new class of antineoplastic agents because of their potent activity in growth arrest, differentiation, and apoptotic death of cancer cells. The ability of the HDAC inhibitors to upregulate exogenous transgene expression and inhibit interferon (IFN) responses prompted our exploration of their use in improving the antitumor efficacy of oncolytic HSV. We discovered that the yield of viral progeny increased significantly when cultured glioma cells were treated with HDAC inhibitors before viral infection. Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Pretreatment with VPA inhibited the induction of several IFN-responsive antiviral genes, augmented the transcriptional level of viral genes, and improved viral propagation, even in the presence of type I IFNs. Moreover, VPA pretreatment improved the propagation and therapeutic efficacy of oncolytic HSV in a human glioma xenograft model in vivo. These findings indicate that HDAC inhibitors can improve the efficacy of tumor virotherapies.

Original languageEnglish
Pages (from-to)1546-1555
Number of pages10
JournalMolecular Therapy
Volume16
Issue number9
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Oncolytic Viruses
Histone Deacetylase Inhibitors
Valproic Acid
Virus Diseases
Simplexvirus
Glioma
Interferons
Neoplasms
Histone Deacetylases
Viral Genes
Transgenes
Heterografts
Antineoplastic Agents
Anticonvulsants
Antiviral Agents
Cultured Cells
Cell Death
Up-Regulation
Therapeutics
Growth

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. / Otsuki, Akihiro; Patel, Ankita; Kasai, Kazue; Suzuki, Masataka; Kurozumi, Kazuhiko; Chiocca, E. Antonio; Saeki, Yoshinaga.

In: Molecular Therapy, Vol. 16, No. 9, 2008, p. 1546-1555.

Research output: Contribution to journalArticle

Otsuki, A, Patel, A, Kasai, K, Suzuki, M, Kurozumi, K, Chiocca, EA & Saeki, Y 2008, 'Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses', Molecular Therapy, vol. 16, no. 9, pp. 1546-1555. https://doi.org/10.1038/mt.2008.155
Otsuki, Akihiro ; Patel, Ankita ; Kasai, Kazue ; Suzuki, Masataka ; Kurozumi, Kazuhiko ; Chiocca, E. Antonio ; Saeki, Yoshinaga. / Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. In: Molecular Therapy. 2008 ; Vol. 16, No. 9. pp. 1546-1555.
@article{6e5b86a8b6044ee99215be3557fd5c10,
title = "Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses",
abstract = "Replication-conditional (oncolytic) mutants of herpes simplex virus (HSV), are considered promising therapeutic alternatives for human malignancies, and chemotherapeutic adjuvants are increasingly sought to augment their efficacy. Histone deacetylase (HDAC) inhibitors are a new class of antineoplastic agents because of their potent activity in growth arrest, differentiation, and apoptotic death of cancer cells. The ability of the HDAC inhibitors to upregulate exogenous transgene expression and inhibit interferon (IFN) responses prompted our exploration of their use in improving the antitumor efficacy of oncolytic HSV. We discovered that the yield of viral progeny increased significantly when cultured glioma cells were treated with HDAC inhibitors before viral infection. Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Pretreatment with VPA inhibited the induction of several IFN-responsive antiviral genes, augmented the transcriptional level of viral genes, and improved viral propagation, even in the presence of type I IFNs. Moreover, VPA pretreatment improved the propagation and therapeutic efficacy of oncolytic HSV in a human glioma xenograft model in vivo. These findings indicate that HDAC inhibitors can improve the efficacy of tumor virotherapies.",
author = "Akihiro Otsuki and Ankita Patel and Kazue Kasai and Masataka Suzuki and Kazuhiko Kurozumi and Chiocca, {E. Antonio} and Yoshinaga Saeki",
year = "2008",
doi = "10.1038/mt.2008.155",
language = "English",
volume = "16",
pages = "1546--1555",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses

AU - Otsuki, Akihiro

AU - Patel, Ankita

AU - Kasai, Kazue

AU - Suzuki, Masataka

AU - Kurozumi, Kazuhiko

AU - Chiocca, E. Antonio

AU - Saeki, Yoshinaga

PY - 2008

Y1 - 2008

N2 - Replication-conditional (oncolytic) mutants of herpes simplex virus (HSV), are considered promising therapeutic alternatives for human malignancies, and chemotherapeutic adjuvants are increasingly sought to augment their efficacy. Histone deacetylase (HDAC) inhibitors are a new class of antineoplastic agents because of their potent activity in growth arrest, differentiation, and apoptotic death of cancer cells. The ability of the HDAC inhibitors to upregulate exogenous transgene expression and inhibit interferon (IFN) responses prompted our exploration of their use in improving the antitumor efficacy of oncolytic HSV. We discovered that the yield of viral progeny increased significantly when cultured glioma cells were treated with HDAC inhibitors before viral infection. Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Pretreatment with VPA inhibited the induction of several IFN-responsive antiviral genes, augmented the transcriptional level of viral genes, and improved viral propagation, even in the presence of type I IFNs. Moreover, VPA pretreatment improved the propagation and therapeutic efficacy of oncolytic HSV in a human glioma xenograft model in vivo. These findings indicate that HDAC inhibitors can improve the efficacy of tumor virotherapies.

AB - Replication-conditional (oncolytic) mutants of herpes simplex virus (HSV), are considered promising therapeutic alternatives for human malignancies, and chemotherapeutic adjuvants are increasingly sought to augment their efficacy. Histone deacetylase (HDAC) inhibitors are a new class of antineoplastic agents because of their potent activity in growth arrest, differentiation, and apoptotic death of cancer cells. The ability of the HDAC inhibitors to upregulate exogenous transgene expression and inhibit interferon (IFN) responses prompted our exploration of their use in improving the antitumor efficacy of oncolytic HSV. We discovered that the yield of viral progeny increased significantly when cultured glioma cells were treated with HDAC inhibitors before viral infection. Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Pretreatment with VPA inhibited the induction of several IFN-responsive antiviral genes, augmented the transcriptional level of viral genes, and improved viral propagation, even in the presence of type I IFNs. Moreover, VPA pretreatment improved the propagation and therapeutic efficacy of oncolytic HSV in a human glioma xenograft model in vivo. These findings indicate that HDAC inhibitors can improve the efficacy of tumor virotherapies.

UR - http://www.scopus.com/inward/record.url?scp=50549097330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549097330&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.155

DO - 10.1038/mt.2008.155

M3 - Article

C2 - 18648350

AN - SCOPUS:50549097330

VL - 16

SP - 1546

EP - 1555

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 9

ER -